Interactive Behavioral Health Psychologist Persona

By | Projects | No Comments

International Space Medicine Consortium Inc with support from its affiliate company, Forever Identity (www.foreverIdentity.it) in Milan/Genoa Italy, have applied our patented (issued and Pending) Dialog stimuli recognition management, emotion/empathy platform and ethical/morality AI subset to space medicine applications.  This scientific/engineering research and application specific product development is further supported by our internal research and development AI, HCI /Voice Recognition, Expert Systems team, consultants and subcontractors. We seek and engage AI partners for NLG and machine learning.

ISMC has created a model for an Interactive Behavioral Health Psychologist for space mission long term group isolations. In association with leading psychologists who focus on emotional intelligence and analysis of facial expression, ISMC’s Senior Advisor on Human Persona Robotics HCI has created an emotional, empathetic Persona that can interact with a person through biosensors and expert psychological behavioral health knowledge. The interaction is compared to an individual baseline emotional pattern to changes measured during the present interaction. Facial expression, biosensors, body movements and voice modulations will be integrated into the Persona through its Hierarchy Matrix that prioritizes input importance. The Persona has the ability to learn and interact with evolving emotional and behavior health changes.

The evolution of this Behavioral Health Psychologist Persona can be used on an everyday basis on earth. Initially it can be used for people or groups in isolated positions. Eventually the Persona through AI will fill the void occurring due to the decreasing number of psychiatrists and behavioral health workers. Once an early detection of a behavioral health problem is identified, modalities of treatment, such as cognitive therapy, can be suggested.

ISMC welcomes experts, universities, government and corporate partners who can help the evolution of the Behavioral Health Psychologist Persona and who can assist our team to create Cognitive Treatment Intelligence for the Persona to suggest treatments to counter the emotional changes realized.

The effects of e‐peptide on breast cancer Tumor cells and mesenchymal stem cells in microgravity

By | Projects | No Comments

ISMC, and its affiliate company, E-P Therapeutics Inc, have been studying the application of our discovery and patent protected Human E-Peptide (designated as hEb) in microgravity as a part of our interest in the Humans in Space and Microbes in Space programs.  The hEb has been shown to down-regulate malignant cellular growth and kill many different malignant cell lines by apoptosis.  Cancer cells that have been studied are:

  • Breast cancer cells (MDA-MB-231 and ZR-75-1)
  • Colon cancer cells (HT29)
  • Hepatoma cells (HepG2)
  • Leukemia cells
  • Neuroblastoma cells (SK-N-F1)
  • Ovarian cancer cells (SKOV and OVCAR)
  • Protease cancer cells (PC3)
  • Small lung cancer cells (NCI-H526F)

Our hEb represents the cleavage of the terminal carboxy end of a pro-IGF-1 molecule. When cleavage occurs, IGF-1 is released and hEb is found as independent molecules. It is water soluble and heat-resistant, and it also has an anti-angiogenesis effect by inhibiting endothelial cell growth. There is evidence that hEb has an inhibitory effect on malignant stem cells.

Studies demonstrate that mesenchymal stem cells (MSC) enhance neoplastic growth while others demonstrate an anti-tumorigenic quality. It is known that MSC have the ability to migrate to tumor sites and react with tumors. MSC can also respond to inflammation around the tumor and deliver cytokines, necrosis factor and interleukin-6, around the tumor environment. The interaction of hEb and mesenchymal stem cells should potentiate tumor necrosis.

 

Our ISMC research has considered the hyper-G and micro-G challenges associated with transport to the ISS. We understand that the proliferation of malignant MDA-MB231 breast cancer cells in microgravity to be greater than the same tumor cells grown at 1G.  Our aim is to test the ability of hEb to respond to faster growing tumor cells and demonstrate its ability to function in a very aggressive environment. MDA-MB231 breast cancer cells in micro-gravity have cell survival up-regulated. This will challenge hEb’s ability to kill cancer cells by apoptosis. Mesenchymal Stem Cells will also be tested against the breast cancer cells to evaluate its effect on tumor growth. The effect of E-Peptide on MSC will also be observed. If successful, this study would demonstrate the potential for hEb to be developed as a novel chemotherapeutic agent. It will also show the effects of Mesenchymal Stem Cells on tumor growth and its use in cancer treatment.

 

ISMC welcomes inquiries from research organizations, universities, government and corporate partners to accelerate our project and to participate in the health and well-being of humanity in the exploration of space and interplanetary colonization.

Life Support Systems for Manned Mars Missions, Overview

By | News | No Comments

Congratulations to ISMC Board member & Chief Medical Officer Dr. Thais Russomano on the publication of her book chapter – Life Support Systems for Manned Mars Missions, Overview –  a part of the Handbook of Life Support Systems for Spacecraft and Extraterrestrial Habitats, Published by Springer International Publishing. This Living Reference Work will develop and grow over the coming months to focus on all aspects of a manned trip to Mars, for example, the climate that will await space travelers, the life support systems necessary to keep them alive on the journey and on the planet, the dangers posed by space radiation, and the physical and psychological effects of living in an extreme environment 54.6 million kilometers away from friends and family on Earth.

Dr. Russomano is a leading international authority in Space Life Sciences, specializing in the effects of low-gravity and microgravity environments on the human body. She is a published author of numerous scientific articles in peer-reviewed journals and Chapters in books, as well as having published 6 books in the areas of Astronomy, the Space Life Sciences, and Aerospace Biomedical Engineering.

The Chapter abstract (doi: 10.1007/978-3-319-09575-2_188-2) can be accessed at the Springer Link website.

#Mars #SpaceTravel

ISMC STEM/STEAM SUPPORT OF SCIENCE DAYS 2017 IN Brazil

By | News, Projects | No Comments

The Science Days 2017 was held from March 12th – March 18th in Brazil to raise awareness of the benefits of STEM worldwide.

Science Days was created based on Florida’s Space Day which is a milestone event that presents an opportunity to educate and bring awareness to legislators and general public on the significance of the aerospace industry and its impact on Florida’s economy.

​In Brazil, Science Days are held on school and university campuses and are administered by the BFCC Board Council, School Councilperson, and the University Council. Currently two very reputable schools and universities will host Science Days Brazil.

#Edutainment #AE

For more information visit http://www.brazilflorida.org/

Steven M. Diamond, DO, MBA is elected to the ISMC Board of Directors and will also serve as the COO of the Consortium

By | Press Release | No Comments

PRESS RELEASE 

29th September 2014

Stevediamond_edited-1

Steven M. Diamond, DO, MBA is elected to the ISMC Board of Directors
and will also serve as the COO of the Consortium

It is a pleasure to announce the nomination and election of Dr. Steven Diamond to the International Space Medicine Consortium Board of Directors and to the appointment as President and Chief Operating Officer. Dr. Diamond’s multifaceted knowledge across multiple fields of medicine including pathology, physiology, pathophysiology, hematopathology, and telemedicine combined with his business development and leadership expertise brings important depth to the ISMC board and corporate operations as it pursues its mission.

Dr. Diamond is a practicing physician, medical examiner and medical entrepreneur. He is currently Director of Laboratories at Hunterdon Medical Center in Flemington, NJ. In addition, he is Medical Director, LabCorp National Clinical Trials Laboratory; Medical Director, Tandem Laboratories, a clinical research organization; Associate Director, Miller-Keystone Memorial Blood Bank and Hunterdon County (NJ) Medical Examiner. Dr. Diamond received his Doctor of Osteopathic Medicine (DO) from Mid-Western University, Chicago, IL and did his residencies pathology at the University of Wisconsin, Philadelphia Naval Hospital and Thomas Jefferson University. He is board certified in Anatomic and Clinical Pathology and is also board certified in Hematopathology. Dr. Diamond is a forensic pathologist and is boarded by the American Board of Medicolegal Death Investigators.

Dr. Diamond received his MBA from the Wharton School of Business at the University of Pennsylvania. His business experience includes:
• Developer and general partner of a physician-owned MRI center involving limited partners who were neurologists, neurosurgeons and orthopedic surgeons at Muhlenberg Hospital, Bethlehem, PA;
• CEO, Medinfocare – a medical software company that provided medical triage information. The company was a Ben Franklin Technology Grant awardee;
• CEO, MyTravelMate – a portable synoptic medical chart with travel emergency call capability. Dr. Diamond holds the patent for this technology;
• Lead developer, Telepathology with a national pathology laboratory to export pathology slides to a foreign venue; and
• Co-founder and Board Member, EP Therapeutics, a biotechnology company focusing on cancer treatment.

Dr. Diamond is a past member of the Management Resource Committee of the College of American Pathologists where he developed the Virtual Business College for pathologists. He also taught graduate courses in the Business of Medicine at Lehigh University’s College of Business. He is a member of the College of American Pathologists, American board of Medicolegal Death Investigators and the Medical Society of Pennsylvania.

The ISMC Board of Directors will now include Dr. Steven Diamond, ISMC COO, Dr Thais Russomano, ISMC Chief Medical Officer, Mr Jim McCarthy and I. The ISMC Board of Directors and Executive Team are very excited to have Steve support our founding vision: to advance the state-of-the-art in the innovative field of space medicine and to collaborate with leading space communities and organizations in the exciting area of human space exploration.

Please join us in congratulating and welcoming Steve to ISMC.

Sincerely,

Barry Ressler

Chairman, Board of Directors

International Space Medicine Consortium, ISMC

Contact:  info@spacemedicineconsortium.com

 

For more information about ISMC, please visit: Website: www.spacemedicineconsortium.com